Entera Bio Ltd (NASDAQ:ENTX) — Market Cap & Net Worth
Market Cap & Net Worth: Entera Bio Ltd (ENTX)
Entera Bio Ltd (NASDAQ:ENTX) has a market capitalization of $64.20 Million ($64.20 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21027 globally and #4748 in its home market, demonstrating a 6.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Entera Bio Ltd's stock price $3.03 by its total outstanding shares 45857242 (45.86 Million). Also see how large is Entera Bio Ltd's balance sheet for a full breakdown of the balance sheet.
Entera Bio Ltd Market Cap History: 2018 to 2026
Entera Bio Ltd's market capitalization history from 2018 to 2026. Data shows change from $139.86 Million to $138.95 Million (-8.48% CAGR). Also see cash efficiency ratio of Entera Bio Ltd for how efficiently the company converts equity into cash flow.
Index Memberships
Entera Bio Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #609 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2020 of 3165 |
Weight: Entera Bio Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Entera Bio Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Entera Bio Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Entera Bio Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
537.11x
Entera Bio Ltd's market cap is 537.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $139.86 Million | $500.00K | -$10.30 Million | 279.73x | N/A |
| 2019 | $98.13 Million | $236.00K | -$10.79 Million | 415.82x | N/A |
| 2020 | $49.53 Million | $365.00K | -$9.98 Million | 135.69x | N/A |
| 2021 | $129.09 Million | $571.00K | -$12.19 Million | 226.07x | N/A |
| 2022 | $33.48 Million | $134.00K | -$13.07 Million | 249.82x | N/A |
| 2023 | $27.51 Million | $14.00K | -$8.89 Million | 1965.31x | N/A |
| 2024 | $97.22 Million | $181.00K | -$9.54 Million | 537.11x | N/A |
Competitor Companies of ENTX by Market Capitalization
Companies near Entera Bio Ltd in the global market cap rankings as of September 18, 2026. Review ENTX intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Entera Bio Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Entera Bio Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Entera Bio Ltd's market cap moved from $139.86 Million to $ 138.95 Million, with a yearly change of -8.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $138.95 Million | +56.19% |
| 2025 | $88.96 Million | -8.49% |
| 2024 | $97.22 Million | +253.33% |
| 2023 | $27.51 Million | -17.81% |
| 2022 | $33.48 Million | -74.07% |
| 2021 | $129.09 Million | +160.65% |
| 2020 | $49.53 Million | -49.53% |
| 2019 | $98.13 Million | -29.84% |
| 2018 | $139.86 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Entera Bio Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $64.20 Million USD |
| MoneyControl | $64.20 Million USD |
| MarketWatch | $64.20 Million USD |
| marketcap.company | $64.20 Million USD |
| Reuters | $64.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more